Legal Barriers
The article contrasts Schedule I status with a 2003 U.S. government patent on CBD as an antioxidant and neuroprotectant. U.S. cannabis research is described as constrained by scheduling barriers, leaving evidence anecdotal or dependent on…
1 sources - 4 claims
The article contrasts Schedule I status with a 2003 U.S. government patent on CBD as an antioxidant and neuroprotectant. U.S. cannabis research is described as constrained by scheduling barriers, leaving evidence anecdotal or dependent on other countries. Federal Schedule I classification is described as a major obstacle to cannabis research, physician education, funding, clinical progress, and access.